For the roughly seven million Americans living with Alzheimer’s disease, the arrival of amyloid-clearing drugs has been shadowed by a stubborn practical barrier: getting the medicine required repeated trips to an infusion center. That is beginning to change. Federal regulators have cleared a version of one of the leading Alzheimer’s therapies that patients or their caregivers can inject at home, from the very first dose, removing the standing appointments that kept many eligible people from ever starting treatment.
The shift matters because logistics, not just biology, has limited who benefits from this class of drugs. Twice-monthly infusions for a year and a half are a heavy lift for aging patients, rural families and overtaxed caregivers. An at-home starter option reframes what beginning treatment looks like.
What the FDA actually cleared
In mid-July 2026, the Food and Drug Administration approved a once-weekly subcutaneous version of lecanemab, sold as Leqembi Iqlik, as a starting dose for early Alzheimer’s disease. According to the drug’s developer, Eisai’s announcement of the approval, the initiation regimen is 500 milligrams once a week, delivered as two 250-milligram injections that each take about 15 seconds and are given through an autoinjector device. The company said it is the first anti-amyloid treatment that can be administered under the skin across the entire course of therapy, from initiation through long-term maintenance. A commercial launch through specialty pharmacies was planned for late August 2026.
Why the infusion barrier mattered so much
Until this clearance, patients beginning lecanemab faced intravenous infusions roughly every two weeks for 18 months before they could transition to any at-home option. The Alzheimer’s Association welcomed the decision as a step that could widen access, noting that the repeated clinic visits imposed real burdens on people with the disease and on the family members who drive them, sit with them and rearrange their lives around the schedule. Removing that requirement at the point of initiation is significant precisely because the early window, when cognitive symptoms are still mild, is when the drug is indicated and when many patients previously stalled before ever getting started.
The clinical evidence behind subcutaneous dosing
Regulators based the approval on data showing the injected form behaves much like the infusion. The FDA prescribing information for lecanemab reflects a therapy that is a humanized monoclonal antibody targeting the amyloid-beta protein thought to drive the disease. Sub-studies drawn from the long-term extension of the pivotal Clarity AD trial found that once-weekly subcutaneous administration achieved drug exposure equivalent to intravenous dosing, supporting comparable clearing of amyloid from the brain. The overall safety profile was broadly similar to the infusion, though injection-site reactions occurred; most were localized rather than systemic. In an acceptability study, 94 percent of patients and care partners rated the device easy to use.
The risks that do not disappear
Moving the shot into the living room does not change lecanemab’s most serious known hazard. The therapy carries a boxed warning for amyloid-related imaging abnormalities, or ARIA, a category that includes brain swelling and small bleeds that are usually detected only through periodic MRI scans. Those imaging appointments, and the clinical oversight that goes with them, remain part of treatment regardless of how the drug itself is delivered. The convenience gain is in the dosing, not in the monitoring, and physicians still screen candidates carefully, including for genetic factors that raise ARIA risk. The drug is also not a cure; it modestly slows cognitive decline in early disease rather than reversing it.
What it signals for Alzheimer’s care
The clearance fits a broader trend of pulling complex therapies out of hospitals and into homes, a move that can preserve scarce infusion-center capacity for patients who need it while lowering the practical cost of staying on treatment. For families, the potential upside is fewer missed doses and less disruption; for the health system, it is a test of whether at-home administration can broaden the reach of amyloid drugs without eroding the safety framework built around them. The medicine remains expensive and appropriate only for a specific early-stage population, so the change is not a universal fix. But by attacking the access problem rather than the biology, the decision addresses one of the most common reasons eligible patients never began therapy at all.
The clearance also lands amid a broader push to diagnose Alzheimer’s earlier, including newer blood-based tests that can flag amyloid buildup before symptoms become severe. A therapy that only helps in the mild stage is of limited value if patients are not identified until later, so easier diagnosis and easier dosing reinforce each other. Whether the at-home option meaningfully widens the treated population will become clearer once the launch is under way and insurers, prescribers and specialty pharmacies work out how patients are screened, trained on the device and monitored for the imaging complications that remain part of the regimen.
This article was produced with AI assistance and reviewed by the Morning Overview editorial team.
More from Morning Overview
